Skip to main content
SpringerLink
Log in

Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen

  • Articles
  • VP16-213 Breast Cancer Adriamycin Short Report
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Conclusions

The combination of adriamycin and VP16-213 has some effect in breast carcinoma resistant to CMF treatment.

The response rates were lower than those obtained with other combinations of adriamycin and other cytostatics and even lower than some responses reported for adriamycin as a single agent.

The best results are apparently obtained when VP-213 is administered for 5 days.

Tolerance is acceptable although hematologic and gastrointestinal toxicities are important.

We do not recommend this combination for the treatment of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ahmann DL, Bisel HP, Eagan RT, Edmonson JH, Hahn RG (1974) Controlled evaluation of adriamycin (NSC-123127) in patienst with diseminated breast cancer. Cancer Chemo Ther Rep 58: 877–882

    Google Scholar 

  2. Baena LF, Perez R, Madrigal LP, Perez G, Vicente J, Montero JM (1977) Resultados preliminares en el trataminto de las metastasis intracraneales (SNC) por cancer de mama con VP 16213. Oncologia 80: 104–111

    Google Scholar 

  3. Eagan RT (1978) Clinical investigation of podophyllotoxin derivatives at the Mayo Clinic. Chemother. Foundation Symposium III, October 27–28 Plaza Hotel, New York, NY, p 41

  4. Issel BF, Crooke ST (1979) Etoposide (VP 16-213). Cancer Treat Rev 6: 107–124

    Google Scholar 

  5. Jones SE, Durie BGM, Salmon SD (1975) Combination chemotherapy with Adriamycin and Cyclophosphamide for advanced breast cancer. Cancer 36: 90–97

    Google Scholar 

  6. Rubin J, Decker DA, Ahmann DL, Eagan RT, Ingle JN, Hahn RG (1980) An evaluation of two schedules of VP16-213 and adriamycin in patients with advanced breast cancer. Oncology 37: 149–151

    Google Scholar 

  7. Scell FC, Yap HY, Hortobacyi GN, Buzdar AU, Blumenschein GR, Issel B, Esparza L (1981) Phase II study of VP16-213 (Etoposide) in refractary metastatic breast cancer. Proc Am Soc Clin Oncol 22: 357

    Google Scholar 

  8. Tranum B, Hoogstraten B (1976) Adriamycin in combination for treatment of breast cancer. Proc Am Soc Clin Oncol 17: 242

    Google Scholar 

  9. Van Echo DA, Aisner J, Wiernik PH, Morris D, Serpick A (1979) Combination chemotherapy of advanced breast cancer with Adriamycin and VP16-213. Proc Am Assoc Cancer Res 20: 228

    Google Scholar 

  10. Wasserman TH, Comis RL, Goldsmith M, Handelsman H, Penta JS, Slavik M, Soper WT, Carter SK (1975) Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep 6: 399–419

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Oncologico Provincial, C/Maiquez, 7, Madrid 9, Spain

    G. Perez Manga, P. Madrigal Alonso & H. Alburquerque Carbuccia

Authors
  1. G. Perez Manga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Madrigal Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Alburquerque Carbuccia
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manga, G.P., Alonso, P.M. & Carbuccia, H.A. Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen. Cancer Chemother. Pharmacol. 7, 231–233 (1982). https://doi.org/10.1007/BF00254557

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254557

Keywords

Search

Navigation